MTOR and non-small cell lung carcinoma: investigated the anti-cancer effect of FGFC1 using erlotinib-resistant non-small cell lung cancer and concluded that the anticancer effect of FGFC1 was mediated by the EGFR/PI3K/Akt/mTOR pathway (Yan et al., 2022).